Aardvark Therapeutics, Inc.

Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

FDA lifted clinical hold on ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome (PWS)